Literature DB >> 7512465

Calcium antagonists and ACE inhibitors. Effect on endothelium and vascular smooth muscle.

T F Lüscher1, Z Yang.   

Abstract

The effects of cardiovascular drugs on endothelium and vascular smooth muscle function are important for the prevention of cardiovascular disease. Changes in endothelial function are an early event in most forms of cardiovascular disease and, later in the disease process, vascular smooth muscle cells are functionally altered and begin to migrate to and proliferate in the intima. Calcium antagonists and angiotensin converting enzyme (ACE) inhibitors are widely used in patients with cardiovascular disease and are thought to have vascular protective effects. ACE, an enzyme located in the endothelial cell membrane, activates angiotensin I and angiotensin II, and deactivates bradykinin. Bradykinin activates endothelial bradykinin (B2) receptors, which results in the formation of nitric oxide and prostacyclin. Hence, ACE inhibitors not only prevent the formation of angiotensin II, but also increase the local levels of bradykinin and in turn nitric oxide and prostacyclin. These compounds are vasodilators and potent inhibitors of platelet function, and therefore may mediate important protective effects of ACE inhibitors. Furthermore, nitric oxide may have antiproliferative effects in vascular smooth muscle cells. Calcium antagonists do not appear to affect the release of endothelium-derived relaxing factors or any other endothelial product. However, they facilitate endothelium-dependent relaxation and reduce the contracting effects of endothelin-1 at the level of smooth muscle. Indeed, in some blood vessels, e.g. the large coronary arteries and the human forearm circulation, verapamil and nifedipine antagonise endothelin-induced contractions. In addition, calcium antagonists inhibit the effects of platelet-derived growth factor and may have antiproliferative effects in vascular smooth muscle cells. In conditions involving progressive dysfunction of the endothelium, vascular deposition of platelets increases the local levels of platelet-derived growth factor, and the antiproliferative effects of calcium antagonists may thus be particularly important.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7512465     DOI: 10.2165/00003495-199300462-00021

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  40 in total

1.  Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase.

Authors:  D S Bredt; P M Hwang; C E Glatt; C Lowenstein; R R Reed; S H Snyder
Journal:  Nature       Date:  1991-06-27       Impact factor: 49.962

2.  Endothelins come home to roost.

Authors:  J Vane
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

3.  Role of calcium in the activation of endothelial cells.

Authors:  A Johns; A D Freay; D J Adams; T W Lategan; U S Ryan; C van Breemen
Journal:  J Cardiovasc Pharmacol       Date:  1988       Impact factor: 3.105

4.  The effects of Ca2+ antagonists on isolated rat and rabbit mesenteric resistance vessels. What determines the sensitivity of agonist-activated vessels to Ca2+ antagonists?

Authors:  C Cauvin; M Tejerina; O Hwang; M Kai-Yamamoto; C van Breemen
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

Review 5.  The pathogenesis of atherosclerosis--an update.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1986-02-20       Impact factor: 91.245

6.  Correlation of platelet calcium with blood pressure. Effect of antihypertensive therapy.

Authors:  P Erne; P Bolli; E Bürgisser; F R Bühler
Journal:  N Engl J Med       Date:  1984-04-26       Impact factor: 91.245

Review 7.  Molecular and cellular biology of endothelin and its receptors--Part II.

Authors:  T F Lüscher; B S Oemar; C M Boulanger; A W Hahn
Journal:  J Hypertens       Date:  1993-02       Impact factor: 4.844

8.  Histamine-induced phosphoinositide metabolism in cultured human umbilical vein endothelial cells. Association with thromboxane and prostacyclin release.

Authors:  T J Resink; A K Moldabaeva; S M Danilov; F R Bühler
Journal:  Biochem Biophys Res Commun       Date:  1987-04-14       Impact factor: 3.575

9.  Calcium antagonists differently inhibit proliferation of human coronary smooth muscle cells in response to pulsatile stretch and platelet-derived growth factor.

Authors:  Z Yang; G Noll; T F Lüscher
Journal:  Circulation       Date:  1993-09       Impact factor: 29.690

10.  Endothelin stimulates phospholipase C in cultured vascular smooth muscle cells.

Authors:  T J Resink; T Scott-Burden; F R Bühler
Journal:  Biochem Biophys Res Commun       Date:  1988-12-30       Impact factor: 3.575

View more
  9 in total

Review 1.  Endothelial dysfunction and hypertension.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 2.  [Therapeutic options for improvement of myocardial perfusion in coronary atherosclerosis].

Authors:  V Schächinger
Journal:  Herz       Date:  1998-03       Impact factor: 1.443

3.  Facilitation of the vasorelaxant action of calcium antagonists by basal nitric oxide in depolarized artery.

Authors:  S Salomone; C L Silva; N Morel; T Godfraind
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

Review 4.  Antihypertensive drugs and reversing of endothelial dysfunction in hypertension.

Authors:  S Taddei; A Virdis; L Ghiadoni; I Sudano; A Salvetti
Journal:  Curr Hypertens Rep       Date:  2000-02       Impact factor: 5.369

Review 5.  Is hypertension a prothrombotic state?

Authors:  George I Varughese; Gregory Y H Lip
Journal:  Curr Hypertens Rep       Date:  2005-06       Impact factor: 5.369

Review 6.  Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension.

Authors:  J C Gillis; A Markham
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 7.  Microvascular Coronary Dysfunction-an Overview.

Authors:  Sahar Naderi
Journal:  Curr Atheroscler Rep       Date:  2018-01-30       Impact factor: 5.113

8.  Cardiomyopathy development protection after myocardial infarction in rats: Successful competition for major dihydropyridines' common metabolite against captopril.

Authors:  Katarzyna A Mitręga; Adrianna M Spałek; Jerzy Nożyński; Maurycy Porc; Magdalena Stankiewicz; Tadeusz F Krzemiński
Journal:  PLoS One       Date:  2017-06-21       Impact factor: 3.240

9.  Dihydropyridines' metabolites-induced early apoptosis after myocardial infarction in rats; new outlook on preclinical study with M-2 and M-3.

Authors:  Katarzyna A Mitręga; Jerzy Nożyński; Maurycy Porc; Adrianna M Spałek; Tadeusz F Krzemiński
Journal:  Apoptosis       Date:  2016-02       Impact factor: 4.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.